Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 2/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2790425 | 0.91 | DDB1 (0.49) | DDB1CRBNSLC18A3SIGMAR1GAA | |
| SCHEMBL15624284 | 0.82 | ESR2 (0.60) | ESR2 | |
| SCHEMBL9705417 | 0.82 | TACR1 (0.42) | DDB1CRBNESR2PKM | |
| SCHEMBL3159001 | 0.79 | MAPK1 (0.56) | GAAMAPTHPGDMAPK1MTNR1A | |
| SCHEMBL3150368 | 0.79 | MAPK1 (0.56) | GAAMAPTHPGDMAPK1MTNR1A | |
| SCHEMBL531338 | 0.79 | MAPK1 (0.56) | GAAMAPTHPGDMAPK1MTNR1A | |
| Hydrochloric Acid SCHEMBL29540251 | 0.77 | MAPK1 (0.55) | GAAMAPTHPGDMAPK1MTNR1A | |
| SCHEMBL4889595 | 0.74 | SLC18A3 (0.57) | DDB1CRBNSLC18A3SIGMAR1GAA | |
| SCHEMBL2937477 | 0.74 | SLC18A3 (0.57) | DDB1CRBNSLC18A3SIGMAR1GAA | |
| Hydrochloric Acid SCHEMBL9482313 | 0.74 | MAPT (0.55) | SLC18A3GAAMAPTSRD5A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5338861-A | Cleaving lactam N-carboxylate or lactim O-carboxylate with elimination of carbon dioxide by heating in gas or liquid phase | BAYER AKTIENGESELLSCHAFT (DE) | 1994-08-16 | — | — | US | claimed |
| EP-2039694-B1 | CGRP receptor antagonists | MERCK SHARP & DOHME (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-1765805-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-1804919-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-03-30 | — | — | EP | disclosed |
| US-7893052-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2011-02-22 | — | — | US | disclosed |
| US-20100298303-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-11-25 | — | — | US | disclosed |
| US-7772224-B2 | Calcitonin gene-related peptide (CGRP) receptor antagonists such as N-[1-(2,3-Difluorobenzyl)-5-oxo-4-(2,22-trifluoroethyl)-1,4-diazepan-6-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide, used for treating headaches | MERCK SHARP & DOHME CORP. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772224-B2 | Calcitonin gene-related peptide (CGRP) receptor antagonists such as N-[1-(2,3-Difluorobenzyl)-5-oxo-4-(2,22-trifluoroethyl)-1,4-diazepan-6-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide, used for treating headaches | MERCK SHARP & DOHME CORP. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7745427-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745427-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-06-29 | — | — | US | disclosed |
| WO-2005072308-A2 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20040229861-A1 | CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2004-11-18 | — | — | US | disclosed |
| WO-2004091514-A2 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004092166-A2 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| EP-0531673-B1 | Process for the preparation of N-substituted lactams | BAYER AG (DE) | 1996-09-11 | — | — | EP | disclosed |
| US-5338861-A | Cleaving lactam N-carboxylate or lactim O-carboxylate with elimination of carbon dioxide by heating in gas or liquid phase | BAYER AKTIENGESELLSCHAFT (DE) | 1994-08-16 | — | — | US | disclosed |
| EP-0531673-A1 | Process for the preparation of N-substituted lactams | BAYER AG (DE) | 1993-03-17 | — | — | EP | disclosed |
| EP-0220865-B1 | LACTAM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS HYPOTENSIVE AGENTS | SANKYO COMPANY LIMITED (JP) | 1992-07-29 | — | — | EP | disclosed |
| US-4734410-A | Lactam derivatives and their use as hypotensive agents | SANKYO COMPANY LIMITED (JP) | 1988-03-29 | — | — | US | disclosed |
| EP-0220865-A2 | Lactam derivatives, their preparation and their use as hypotensive agents | SANKYO COMPANY LIMITED (JP) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229861-A1 | CGRP receptor antagonists | CCKBR, CCKAR, CALCRL | DDB1 2873/4885CRBN 3676/4885SLC18A3 560/4885 |
| US-20100298303-A1 | CGRP RECEPTOR ANTAGONISTS | CCKBR, BDKRB1, BDKRB2 | DDB1 2746/4885CRBN 3064/4885SLC18A3 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.